These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19199934)

  • 1. Aldose reductase enzyme and its implication to major health problems of the 21(st) century.
    Alexiou P; Pegklidou K; Chatzopoulou M; Nicolaou I; Demopoulos VJ
    Curr Med Chem; 2009; 16(6):734-52. PubMed ID: 19199934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase inhibitors: 2013-present.
    Quattrini L; La Motta C
    Expert Opin Ther Pat; 2019 Mar; 29(3):199-213. PubMed ID: 30760060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
    Nencetti S; La Motta C; Rossello A; Sartini S; Nuti E; Ciccone L; Orlandini E
    Bioorg Med Chem; 2017 Jun; 25(12):3068-3076. PubMed ID: 28392277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
    Kovacikova L; Prnova MS; Majekova M; Bohac A; Karasu C; Stefek M
    Molecules; 2021 May; 26(10):. PubMed ID: 34066081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From a dull enzyme to something else: facts and perspectives regarding aldose reductase.
    Del Corso A; Cappiello M; Mura U
    Curr Med Chem; 2008; 15(15):1452-61. PubMed ID: 18537622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.
    Kumar M; Choudhary S; Singh PK; Silakari O
    Future Med Chem; 2020 Jul; 12(14):1327-1358. PubMed ID: 32602375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aldose reductase inhibitors: a patent survey (2006--present).
    Chatzopoulou M; Alexiou P; Kotsampasakou E; Demopoulos VJ
    Expert Opin Ther Pat; 2012 Nov; 22(11):1303-23. PubMed ID: 22998509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors.
    Balestri F; Quattrini L; Coviello V; Sartini S; Da Settimo F; Cappiello M; Moschini R; Del Corso A; Mura U; La Motta C
    Cell Chem Biol; 2018 Nov; 25(11):1414-1418.e3. PubMed ID: 30122369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of aldose reductase inhibitors for the treatment of inflammatory disorders.
    Chatzopoulou M; Pegklidou K; Papastavrou N; Demopoulos VJ
    Expert Opin Drug Discov; 2013 Nov; 8(11):1365-80. PubMed ID: 24090200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S; Buyukbingol E
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol.
    Smeriglio A; Giofrè SV; Galati EM; Monforte MT; Cicero N; D'Angelo V; Grassi G; Circosta C
    Fitoterapia; 2018 Jun; 127():101-108. PubMed ID: 29427593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose reductase: a novel therapeutic target for inflammatory pathologies.
    Ramana KV; Srivastava SK
    Int J Biochem Cell Biol; 2010 Jan; 42(1):17-20. PubMed ID: 19778627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A non-invasive, multi-target approach to treat diabetic retinopathy.
    Julius A; Hopper W
    Biomed Pharmacother; 2019 Jan; 109():708-715. PubMed ID: 30551523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
    Ibrar A; Tehseen Y; Khan I; Hameed A; Saeed A; Furtmann N; Bajorath J; Iqbal J
    Bioorg Chem; 2016 Oct; 68():177-86. PubMed ID: 27544072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
    Papastavrou N; Chatzopoulou M; Ballekova J; Cappiello M; Moschini R; Balestri F; Patsilinakos A; Ragno R; Stefek M; Nicolaou I
    Eur J Med Chem; 2017 Apr; 130():328-335. PubMed ID: 28259841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies.
    Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M
    Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
    Maccari R; Ottanà R
    J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.